# Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer

> **NCT04557306** · PHASE1 · COMPLETED · sponsor: **CHABiotech CO., Ltd** · enrollment: 6 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** CBT101 cells, every 2 weeks
- **BIOLOGICAL:** CBT101 cells, every 4 weeks

## Key facts

- **NCT ID:** NCT04557306
- **Lead sponsor:** CHABiotech CO., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-21
- **Primary completion:** 2021-10-26
- **Final completion:** 2021-10-26
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04557306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04557306, "Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04557306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*